urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

Latest news

Keytruda gains NICE clearance in first line bladder cancer

Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s treatment within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in ... Pembrolizumab is already
Another Tecentriq win for Roche as Avastin combo boosts survival

Tecentriq is currently approved for previously-treated NSCLC patients and also as a second-line therapy for metastatic urothelial carcinoma, a form of bladder cancer.
NICE says OK to Keytruda for bladder cancer via the CDF

metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. ... Louise Houson, UK managing director for MSD, said: “MSD is really pleased that NICE has recommended pembrolizumab for eligible patients with advanced
MSD’s Keytruda wins bladder cancer indication in Japan

The pharma giant’s blockbuster has gained a new indication to treat patients with previously treated urothelial carcinoma (UC) that is unresectable with radical surgery and whose disease has progressed following ... chemotherapy. Dr Roy Baynes, senior
Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

The drug is already approved as a treatment for rare cancer Merkel cell carcinoma and as a second-line therapy for bladder cancer (metastatic urothelial carcinoma), but Pfizer and Merck are

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Medical Education: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Medical Writer: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Scientific Director – Medical Communications: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

Health Consultant - Brand Comms: Competitive Salary

Senior Account Manager, Medical Communications, London: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Director – Healthcare Advertising – London: Salary TBC

Home based, Senior Medical Writer, Medical Communications: Excellent package

EU Head of Business Development and Client Service: Exceptional packge and bonus

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Digital Health Specialist – Global Agency: Salary TBC

Creative/ Medical Writer: Circa £35, 000 With Benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Programme/ Account Director - Healthcare PR - London: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....